Central nervous system progression during systemic response to trastuzumab, humanized anti-HER-2/neu antibody, plus paclitaxel in a woman with refractory metastatic breast cancer

Susan Lindrud, Michelle Orlick, Nicola Barnard, William N. Hait, Deborah L. Toppmeyer

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Treatment of selected patients with anti-HER-2/neu antibodies alone (1) or in combination with chemotherapy (2) may be of benefit to patients with refractory breast cancer. Approximately 30% of breast cancers overexpress HER-2/neu, a member of the epidermal growth factor receptor family. These patients may have a poorer overall prognosis (3) due to relative resistance to both hormonal therapy and chemotherapy (4-6). We recently observed a patient with refractory breast cancer who responded to rhuMAB HER-2 (trastuzumab) plus paclitaxel after progressing on paclitaxel alone. While on combination treatment she developed cerebellar metastases. Follow-up computed tomography (CT) scan revealed that her disease continued to respond in the liver, lungs, and bone. This case suggests that failure of trastuzumab to cross the blood-brain barrier may compromise its overall effectiveness and raises the possibility that the central nervous system (CNS), or other sanctuary sites, may become clinically more significant in patients with breast cancer in the era of antibody-based therapies.

Original languageEnglish (US)
Pages (from-to)116-119
Number of pages4
JournalBreast Journal
Volume9
Issue number2
DOIs
StatePublished - Mar 2003

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Surgery
  • Oncology

Keywords

  • Blood-brain barrier
  • Breast cancer
  • Paclitaxel
  • Trastuzumab

Fingerprint Dive into the research topics of 'Central nervous system progression during systemic response to trastuzumab, humanized anti-HER-2/neu antibody, plus paclitaxel in a woman with refractory metastatic breast cancer'. Together they form a unique fingerprint.

Cite this